| Compound Information | SONAR Target prediction |
| Name: | COLISTIMETHATE SODIUM |
| Unique Identifier: | SPE01500206 |
| MolClass: | Checkout models in ver1.5 and ver1.0 |
| Molecular Formula: | |
| Molecular Weight: | 1631.98 g/mol |
| X log p: | -11.16 (online calculus) |
| Lipinksi Failures | 2 |
| TPSA | 515.67 |
| Hydrogen Bond Donor Count: | 0 |
| Hydrogen Bond Acceptors Count: | 44 |
| Rotatable Bond Count: | 47 |
| Canonical Smiles: | [Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)CNCCC(NC(=O)CCCCC(C)C)C(=O) NC(C(C)O)C(=O)NC(CCNCS([O-])(=O)=O)C(=O)NC1CCNC(=O)C(NC(=O)C(CCNCS([O- ])(=O)=O)NC(=O)C(CCNCS([O-])(=O)=O)NC(=O)C(NC(=O)C(NC(=O)C(CCNCS([O-]) (=O)=O)NC1=O)C(C)CC)C(C)CC)C(C)O |
| Source: | Bacillus colistinus |
| Reference: | Brit.J.Pharmacol.Chemother. 23: 552 (1964) |
| Therapeutics: | antibacterial |
| Generic_name: | Colistimethate |
| Chemical_iupac_name: | pentasodium [3-[[3-(1-hydroxyethyl)-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-6,9,18- tris[2-(sulfonatomethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]carba moyl]-3-[3-hydroxy-2-[2-(6-methyloctanoylamino)-4-(sulfonatomethylamino)butanoyl]ami no-butanoyl]amino-propyl]aminomethanesulfonate |
| Drug_type: | Approved Drug |
| Kegg_compound_id: | C13553 |
| Drugbank_id: | APRD00885 |
| H2o_solubility: | Appreciable |
| Cas_registry_number: | 8068-28-8 |
| Drug_category: | Antibacterial agents |
| Indication: | For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa. |
| Pharmacology: | Colistimethate is a polymyxin antibiotic agent. Originally, colistimethate sodium was thought to be less toxic than polymyxin B; however, if the drugs are administered at comparable doses, their toxicities may be similar. Polymyxins are cationic polypeptides that disrupt the bacterial cell membrane through a detergentlike mechanism. With the development of less toxic agents, such as extended-spectrum penicillins and cephalosporins, parenteral polymyxin use was largely abandoned, except for the treatment of multidrug-resistant pulmonary infections in patients with cystic fibrosis. More recently, however, the emergence of multidrug-resistant gram-negative bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii, and the lack of new antimicrobial agents have led to the revived use of the polymyxins. |
| Mechanism_of_action: | Colistimethate is a surface active agent which penetrates into and disrupts the bacterial cell membrane. Colistimethate is polycationic and has both hydrophobic and lipophilic moieties. It interacts with the bacterial cytoplasmic membrane, changing its permeability. This effect is bactericidal. There is also evidence that polymyxins enter the cell and precipitate cytoplasmic components, primarily ribosomes. |
| Organisms_affected: | Gram-negative bacilli |
| Found: 205 nonactive | as graph: single | with analogs | 1 2 3 4 5 6 7 8 9 10 Next >> [205] |
| Species: | 4932 |
| Condition: | AAT2 |
| Replicates: | 2 |
| Raw OD Value: r im | 0.7248±0.00233345 |
| Normalized OD Score: sc h | 0.9946±0.00480236 |
| Z-Score: | -0.2867±0.248463 |
| p-Value: | 0.777728 |
| Z-Factor: | -62.9602 |
| Fitness Defect: | 0.2514 |
| Bioactivity Statement: | Nonactive |
| ps |
| DBLink | Rows returned: 5 |
| 2835 | [[3-[[1-[[1-[[12,15-dibutan-2-yl-3-(1-hydroxyethyl)-2,5,8,11,14,17,20-heptaoxo-6,9,18-tris[2-(sulfonatom ethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]carbamoyl]-3-(sulfonatomethylamino)propyl]c arbamoyl]-2-hydroxy-propyl]carbamoyl]-3-(6-methylheptanoylamino)propyl]amino]methanesulfonate |
| 2836 | [[3-[[1-[[1-[[12,15-dibutan-2-yl-3-(1-hydroxyethyl)-2,5,8,11,14,17,20-heptaoxo-6,9,18-tris[2-(sulfomethy lamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]carbamoyl]-3-(sulfomethylamino)propyl]carbamoyl ]-2-hydroxy-propyl]carbamoyl]-3-(6-methylheptanoylamino)propyl]amino]methanesulfonic acid |
| 216258 | pentasodium [[3-[[2-hydroxy-1-[[1-[[3-(1-hydroxyethyl)-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-6,9,18-t ris[2-(sulfonatomethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]carbamoyl]-3-(sulfonatomet hylamino)propyl]carbamoyl]propyl]carbamoyl]-3-(6-methyloctanoylamino)propyl]amino]methanesulfonate |
| 216259 | [[3-[[3-(1-hydroxyethyl)-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-6,9,18-tris[2-(sulfomethyl amino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]carbamoyl]-3-[[3-hydroxy-2-[[2-(6-methyloctanoyl amino)-4-(sulfomethylamino)butanoyl]amino]butanoyl]amino]propyl]amino]methanesulfonic acid |
| 5702027 | pentasodium [[3-[[1-[[1-[[12,15-dibutan-2-yl-3-(1-hydroxyethyl)-2,5,8,11,14,17,20-heptaoxo-6,9,18-tris[2-(sulfonatom ethylamino)ethyl]-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]carbamoyl]-3-(sulfonatomethylamino)propyl]c arbamoyl]-2-hydroxy-propyl]carbamoyl]-3-(6-methylheptanoylamino)propyl]amino]methanesulfonate |
| internal high similarity DBLink | Rows returned: 0 |
| active | Cluster 1 | Additional Members: 50 | Rows returned: 13 | 1 2 3 Next >> |
| LOPAC 00756 | 0 |
| SPE01503692 | 0 |
| LAT007G07 | 0 |
| Prest1291 | 0 |
| LAT007H07 | 0 |
| LAT007E08 | 0 |
Service provided by the
Mike Tyers Laboratory